Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
In clinical trials, the most common adverse reactions reported were neutropenia, hiccups, decreased appetite and dizziness.
The medtech titan was told to make a public apology and remove the content.
The Sapien 3 is a transcatheter aortic valve replacement designed to treat aortic stenosis.
The news was disclosed by Ruyi He, MD, Chief Scientist of the CFDA and the Center for Drug Evaluation.
A cybersecurity expert said the error may leave people vulnerable to hackers.
3SBio reported the CFDA formally approved Bydureon, its once-weekly Glucagon-like peptide-1 receptor agonist for type 2 diabetes treatment.
Dr. Erwin Erfe, head of the PAO Forensic Laboratory, said the 4 children they examined contracted dengue 6 months after receiving the vaccine.
As yet, the company has no products on the market, so the applications, if approved, would mark the company’s shift into a commercial company.
The suit, filed in Nevada Friday, comes after Vtesse was purchased by Sucampo for $200 million in April.
Just before ringing in the new year, Valeant has managed to resolve another crisis.